Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.30 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7017014 | 0.77 | HCAR2 (0.35) | HCAR2HSD17B10LOXL2 | |
| SCHEMBL4326419 | 0.76 | HCAR2 (0.43) | HCAR2HSD17B10LOXL2KDM4E | |
| SCHEMBL7018498 | 0.70 | HCAR2 (0.38) | HCAR2HSD17B10LOXL2KDM4E | |
| SCHEMBL27834761 | 0.70 | MAPT (0.43) | HCAR2HSD17B10KDM4E | |
| SCHEMBL27834705 | 0.68 | CYP19A1 (0.41) | — | |
| SCHEMBL27814966 | 0.67 | CAPN1 (0.41) | — | |
| SCHEMBL194124 | 0.66 | — | — | |
| SCHEMBL12499653 | 0.65 | P4HTM (0.53) | HCAR2HSD17B10KDM4ETBXAS1 | |
| SCHEMBL12499655 | 0.65 | P4HTM (0.53) | HCAR2HSD17B10KDM4ETBXAS1 | |
| Hydrochloric Acid SCHEMBL27333803 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | HCAR2 795/4885HSD17B10 1644/4885LOXL2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.